A Phase II Study of VS-6063 in Patients with Malignant Pleural Mesothelioma

Full Title

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects with Malignant Pleural Mesothelioma


Typically after receiving initial chemotherapy for malignant pleural mesothelioma, patients are monitored. In this study, researchers want to see if giving an investigational drug called VS-6063 to patients with pleural mesothelioma who responded well to initial therapy can extend their lives, reduce the risk of recurrence, and improve their quality of life.

Patients will be randomly assigned to receive VS-6063 or a placebo. VS-6063 works by inhibiting an enzyme called FAK that maintains the structure of mesothelioma cells and helps them move through the body. VS-6063 is a tablet that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have malignant pleural mesothelioma and have responded well to at least four cycles of initial chemotherapy which included pemetrexed and either cisplatin or carboplatin.
  • No more than 6 weeks may have passed since the last dose of initial chemotherapy and entry into the study.
  • All serious side effects of prior treatment should have resolved before entering the study.
  • This study is open to patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Marjorie Zauderer at 646-888-4656.







Krug, Lee, MD